Summit Therapeutics
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 105
- Market Cap
- $9.7B
- Introduction
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Summit Therapeutics
- Target Recruit Count
- 780
- Registration Number
- NCT06767514
- Locations
- 🇺🇸
Clinical Study Site, Webster, Texas, United States
Phase III Study of AK112 for NSCLC Patients
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- Drug: AK112 InjectionDrug: Placebo Injection
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Summit Therapeutics
- Target Recruit Count
- 420
- Registration Number
- NCT06396065
- Locations
- 🇺🇸
CBCC Global Research, Bakersfield, California, United States
🇺🇸UC San Diego, La Jolla, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
HARMONi-3
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Summit Therapeutics Inc.
- Target Recruit Count
- 389
- Registration Number
- 2024-513087-26-00
- Locations
- 🇧🇪
Werken Glorieux, Ronse, Belgium
🇧🇪Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir, Belgium
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
- Conditions
- Clostridioides Difficile Infection
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Summit Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04802837
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸Continental Clinical Research, Miami, Florida, United States
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
- Conditions
- Clostridioides Difficile Infection
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Summit Therapeutics
- Target Recruit Count
- 759
- Registration Number
- NCT03595553
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸GI Alliance - Arizona Digestive Health - Sun City, Sun City, Arizona, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- Prev
- 1
- 2
- Next
News
AstraZeneca and Summit Therapeutics in Advanced Talks for $15 Billion Ivonescimab Licensing Deal
AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.
Revolution Medicines and Summit Therapeutics Launch Clinical Collaboration to Test RAS Inhibitor Combinations with Bispecific Antibody
Revolution Medicines and Summit Therapeutics announced a clinical collaboration to evaluate three RAS(ON) inhibitors in combination with ivonescimab, a PD-1/VEGF bispecific antibody, across multiple solid tumor types.
TOLREMO Therapeutics Strengthens Leadership with Key Appointments as TT125-802 Shows Clinical Promise
TOLREMO therapeutics has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer to strengthen leadership capabilities.
Bristol Myers Squibb Partners with BioNTech in $11.1 Billion Deal for Dual-Target Cancer Immunotherapy
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.
Summit Therapeutics' Ivonescimab Shows Promising Results in Phase 3 NSCLC Trial
Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.
Akeso Secures FDA Approval for Novel Cancer Drug While Partner Summit Therapeutics Faces Sharp Stock Decline
Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.
Summit's Ivonescimab Shows Promise in Phase III Trial Against Established Lung Cancer Therapies
Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.
Akeso Reports Positive Phase 3 Results for Ivonescimab in Lung Cancer, Building on Recent FDA Approval Success
Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.
BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC
BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.
Summit Therapeutics Partners with Pfizer to Evaluate Novel Cancer Drug Combination Amid Financial Losses
Summit Therapeutics announces strategic collaboration with Pfizer to evaluate their cancer drug ivonescimab in combination with Pfizer's antibody drug conjugates for solid tumor treatment.